Oncogenic tyrosine kinases target Dok-1 for ubiquitin-mediated proteasomal degradation to promote cell transformation

Molecular and Cellular Biology

Volumn 31, Issue 13, 2011, Pages 2552-2565

  Janas, Justyna A ^a   Van Aelst, Linda ^a  

^a Howard Hughes Medical Institute Cold Spring Harbor Laboratory Cold Spring Harbor   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADAPTOR PROTEIN; BCR ABL PROTEIN; ONCOPROTEIN; PROTEASOME; PROTEIN DOK 1; PROTEIN TYROSINE KINASE; STEROID RECEPTOR COACTIVATOR PROTEN; UBIQUITIN; UNCLASSIFIED DRUG;

ARTICLE; CARCINOGENESIS; CELL PROLIFERATION; CELL TRANSFORMATION; ENZYME ACTIVITY; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN STABILITY; TUMOR GROWTH; UBIQUITINATION;

CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; DNA-BINDING PROTEINS; DOWN-REGULATION; FUSION PROTEINS, BCR-ABL; HUMANS; LYSINE; PHOSPHOPROTEINS; PROTEASOME ENDOPEPTIDASE COMPLEX; RNA-BINDING PROTEINS; SRC-FAMILY KINASES; UBIQUITIN; UBIQUITINATION;

EID: 79959484704     PISSN: 02707306     EISSN: 10985549     Source Type: Journal    
DOI: 10.1128/MCB.05045-11     Document Type: Article

References (99)

1. Abram, C. L., and S. A. Courtneidge. 2000. Src family tyrosine kinases and growth factor signaling. Exp. Cell Res. 254:1-13.
2. Bache, K. G., T. Slagsvold, and H. Stenmark. 2004. Defective downregulation of receptor tyrosine kinases in cancer. EMBO J. 23:2707-2712.
3. Barnes, D. J., B. Schultheis, S. Adedeji, and J. V. Melo. 2005. Dose-dependent effects of Bcr-Abl in cell line models of different stages of chronic myeloid leukemia. Oncogene 24:6432-6440.
4. Berger, A. H., et al. 2010. Identification of DOK genes as lung tumor suppressors. Nat. Genet. 42:216-223.
5. Berman, E., et al. 2000. Characterization of two novel sublines established from a human megakaryoblastic leukemia cell line transfected with p210(BCR-ABL). Leuk. Res. 24:289-297.
6. Bhat, A., K. J. Johnson, T. Oda, A. S. Corbin, and B. J. Druker. 1998. Interactions of p62(dok) with p210(bcr-abl) and Bcr-Abl-associated proteins. J. Biol. Chem. 273:32360-32368.
7. Blume-Jensen, P., and T. Hunter. 2001. Oncogenic kinase signalling. Nature 411:355-365.
8. Boettner, B., E. E. Govek, J. Cross, and L. Van Aelst. 2000. The junctional multidomain protein AF-6 is a binding partner of the Rap1A GTPase and associates with the actin cytoskeletal regulator profilin. Proc. Natl. Acad. Sci. U. S. A. 97:9064-9069.
9. Bose, R., et al. 2006. Phosphoproteomic analysis of Her2/neu signaling and inhibition. Proc. Natl. Acad. Sci. U. S. A. 103:9773-9778.
10. Bradshaw, R. A., W. W. Brickey, and K. W. Walker. 1998. N-terminal processing: the methionine aminopeptidase and N alpha-acetyl transferase families. Trends Biochem. Sci. 23:263-267.
11. Cadwell, K., and L. Coscoy. 2005. Ubiquitination on nonlysine residues by a viral E3 ubiquitin ligase. Science 309:127-130.
12. Caron, C., C. Boyault, and S. Khochbin. 2005. Regulatory cross-talk between lysine acetylation and ubiquitination: role in the control of protein stability. Bioessays 27:408-415.
13. Carpino, N., et al. 1997. p62(dok): a constitutively tyrosine-phosphorylated, GAP-associated protein in chronic myelogenous leukemia progenitor cells. Cell 88:197-204.
14. Ciechanover, A., and R. Ben-Saadon. 2004. N-terminal ubiquitination: more protein substrates join in. Trends Cell Biol. 14:103-106.
15. Cong, F., B. Yuan, and S. P. Goff. 1999. Characterization of a novel member of the DOK family that binds and modulates Abl signaling. Mol. Cell. Biol. 19:8314-8325.
16. Crowder, R. J., H. Enomoto, M. Yang, E. M. Johnson, Jr., and J. Milbrandt. 2004. Dok-6, a novel p62 Dok family member, promotes Ret-mediated neurite outgrowth. J. Biol. Chem. 279:42072-42081.
17. Dai, Z., et al. 1998. Oncogenic Abl and Src tyrosine kinases elicit the ubiquitin-dependent degradation of target proteins through a Ras-independent pathway. Genes Dev. 12:1415-1424.
18. DeClue, J. E., W. C. Vass, M. R. Johnson, D. W. Stacey, and D. R. Lowy. 1993. Functional role of GTPase-activating protein in cell transformation by pp60v-src. Mol. Cell. Biol. 13:6799-6809.
19. Demers, A., et al. 2009. A concerted kinase interplay identifies PPARgamma as a molecular target of ghrelin signaling in macrophages. PLoS One 4:e7728.
20. Di Cristofano, A., et al. 1998. Molecular cloning and characterization of p56dok-2 defines a new family of RasGAP-binding proteins. J. Biol. Chem. 273:4827-4830.
21. Di Cristofano, A., et al. 2001. p62(dok), a negative regulator of Ras and mitogen-activated protein kinase (MAPK) activity, opposes leukemogenesis by p210(bcr-abl). J. Exp. Med. 194:275-284.
22. Dube, N., A. Cheng, and M. L. Tremblay. 2004. The role of protein tyrosine phosphatase 1B in Ras signaling. Proc. Natl. Acad. Sci. U. S. A. 101:1834-1839.
23. Ellis, C., M. Moran, F. McCormick, and T. Pawson. 1990. Phosphorylation of GAP and GAP-associated proteins by transforming and mitogenic tyrosine kinases. Nature 343:377-381.
24. Fry, W. H., L. Kotelawala, C. Sweeney, and K. L. Carraway III. 2009. Mechanisms of ErbB receptor negative regulation and relevance in cancer. Exp. Cell Res. 315:697-706.
25. Gaiger, A., et al. 1995. Increase of bcr-abl chimeric mRNA expression in tumor cells of patients with chronic myeloid leukemia precedes disease progression. Blood 86:2371-2378.
26. Geoffroy, M. C., and R. T. Hay. 2009. An additional role for SUMO in ubiquitin-mediated proteolysis. Nat. Rev. Mol. Cell Biol. 10:564-568.
27. Giaccone, G., and P. A. Zucali. 2008. Src as a potential therapeutic target in non-small-cell lung cancer. Ann. Oncol. 19:1219-1223.
28. Gorre, M. E., et al. 2001. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293:876-880.
29. Govek, E. E., et al. 2004. The X-linked mental retardation protein oligophrenin-1 is required for dendritic spine morphogenesis. Nat. Neurosci. 7:364-372.
30. Grimm, J., et al. 2001. Novel p62dok family members, dok-4 and dok-5, are substrates of the c-Ret receptor tyrosine kinase and mediate neuronal differentiation. J. Cell Biol. 154:345-354.
31. Guittard, G., et al. 2009. Cutting edge: Dok-1 and Dok-2 adaptor molecules are regulated by phosphatidylinositol 5-phosphate production in T cells. J. Immunol. 182:3974-3978.
32. Hendrie, P. C., K. Miyazawa, Y. C. Yang, C. D. Langefeld, and H. E. Broxmeyer. 1991. Mast cell growth factor (c-kit ligand) enhances cytokine stimulation of proliferation of the human factor-dependent cell line, M07e. Exp. Hematol. 19:1031-1037.
33. Honma, M., et al. 2006. Dok-3 sequesters Grb2 and inhibits the Ras-Erk pathway downstream of protein-tyrosine kinases. Genes Cells 11:143-151.
34. Hosomi, Y., et al. 1994. Characterization of a 60-kilodalton substrate of the insulin receptor kinase. J. Biol. Chem. 269:11498-11502.
35. Hunter, T. 2007. The age of crosstalk: phosphorylation, ubiquitination, and beyond. Mol. Cell 28:730-738.
36. Hunter, T. 2009. Tyrosine phosphorylation: thirty years and counting. Curr. Opin. Cell Biol. 21:140-146.
37. Irby, R. B., and T. J. Yeatman. 2000. Role of Src expression and activation in human cancer. Oncogene 19:5636-5642.
38. Janas, J., J. Skowronski, and L. Van Aelst. 2006. Lentiviral delivery of RNAi in hippocampal neurons. Methods Enzymol. 406:593-605.
39. Jones, N., and D. J. Dumont. 1999. Recruitment of Dok-R to the EGF receptor through its PTB domain is required for attenuation of Erk MAP kinase activation. Curr. Biol. 9:1057-1060.
40. Jones, N., and D. J. Dumont. 1998. The Tek/Tie2 receptor signals through a novel Dok-related docking protein, Dok-R. Oncogene 17:1097-1108.
41. Kerscher, O., R. Felberbaum, and M. Hochstrasser. 2006. Modification of proteins by ubiquitin and ubiquitin-like proteins. Annu. Rev. Cell Dev. Biol. 22:159-180.
42. Kirisits, A., D. Pils, and M. Krainer. 2007. Epidermal growth factor receptor degradation: an alternative view of oncogenic pathways. Int. J. Biochem. Cell Biol. 39:2173-2182.
43. Klucher, K. M., D. V. Lopez, and G. Q. Daley. 1998. Secondary mutation maintains the transformed state in BaF3 cells with inducible BCR/ABL expression. Blood 91:3927-3934.
44. Kobayashi, R., R. Patenia, S. Ashizawa, and J. Vykoukal. 2009. Targeted mass spectrometric analysis of N-terminally truncated isoforms generated via alternative translation initiation. FEBS Lett. 583:2441-2445.
45. Kolch, W., and A. Pitt. 2010. Functional proteomics to dissect tyrosine kinase signalling pathways in cancer. Nat. Rev. Cancer 10:618-629.
46. Krause, D. S., and R. A. Van Etten. 2005. Tyrosine kinases as targets for cancer therapy. N. Engl. J. Med. 353:172-187.
47. Laszlo, G. S., and J. A. Cooper. 2009. Restriction of Src activity by Cullin-5. Curr. Biol. 19:157-162.
48. Lee, Y., and H. E. Broxmeyer. 2001. Synergistic activation of RSK correlates with c-fos induction in MO7e cells stimulated with GM-CSF plus Steel factor. Biochem. Biophys. Res. Commun. 281:897-901.
49. Lemay, S., D. Davidson, S. Latour, and A. Veillette. 2000. Dok-3, a novel adapter molecule involved in the negative regulation of immunoreceptor signaling. Mol. Cell. Biol. 20:2743-2754.
50. Livak, K. J., and T. D. Schmittgen. 2001. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta delta C(T)) method. Methods 25:402-408.
51. Lugo, T. G., A. M. Pendergast, A. J. Muller, and O. N. Witte. 1990. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science 247:1079-1082.
52. Manning, G., D. B. Whyte, R. Martinez, T. Hunter, and S. Sudarsanam. 2002. The protein kinase complement of the human genome. Science 298: 1912-1934.
53. Mashima, R., Y. Hishida, T. Tezuka, and Y. Yamanashi. 2009. The roles of Dok family adapters in immunoreceptor signaling. Immunol. Rev. 232:273-285.
54. Mashima, R., et al. 2010. Mice lacking Dok-1, Dok-2, and Dok-3 succumb to aggressive histiocytic sarcoma. Lab. Invest. 90:1357-1364.
55. Masson, K., and L. Ronnstrand. 2009. Oncogenic signaling from the hematopoietic growth factor receptors c-Kit and Flt3. Cell. Signal. 21:1717-1726.
56. McGillicuddy, L. T., et al. 2009. Proteasomal and genetic inactivation of the NF1 tumor suppressor in gliomagenesis. Cancer Cell 16:44-54.
57. Melo, J. V., and D. J. Barnes. 2007. Chronic myeloid leukaemia as a model of disease evolution in human cancer. Nat. Rev. Cancer 7:441-453.
58. Mihrshahi, R., A. N. Barclay, and M. H. Brown. 2009. Essential roles for Dok2 and RasGAP in CD200 receptor-mediated regulation of human myeloid cells. J. Immunol. 183:4879-4886.
59. Moran, M. F., P. Polakis, F. McCormick, T. Pawson, and C. Ellis. 1991. Protein-tyrosine kinases regulate the phosphorylation, protein interactions, subcellular distribution, and activity of p21ras GTPase-activating protein. Mol. Cell. Biol. 11:1804-1812.
60. Neet, K., and T. Hunter. 1995. The nonreceptor protein-tyrosine kinase CSK complexes directly with the GTPase-activating protein-associated p62 protein in cells expressing v-Src or activated c-Src. Mol. Cell. Biol. 15:4908-4920.
61. Nelms, K., A. L. Snow, J. Hu-Li, and W. E. Paul. 1998. FRIP, a hematopoietic cell-specific rasGAP-interacting protein phosphorylated in response to cytokine stimulation. Immunity 9:13-24.
62. Neviani, P., et al. 2005. The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABLregulated SET protein. Cancer Cell 8:355-368.
63. Niki, M., et al. 2004. Role of Dok-1 and Dok-2 in leukemia suppression. J. Exp. Med. 200:1689-1695.
64. Noguchi, T., et al. 1999. Tyrosine phosphorylation of p62(Dok) induced by cell adhesion and insulin: possible role in cell migration. EMBO J. 18:1748-1760.
65. Nowicki, M. O., et al. 2003. Chronic myelogenous leukemia molecular signature. Oncogene 22:3952-3963.
66. Okada, K., et al. 2006. The muscle protein Dok-7 is essential for neuromuscular synaptogenesis. Science 312:1802-1805.
67. Oki, S., et al. 2005. Dok1 and SHIP act as negative regulators of v-Ablinduced pre-B cell transformation, proliferation and Ras/Erk activation. Cell Cycle 4:310-314.
68. Palacios, R., and M. Steinmetz. 1985. Il-3-dependent mouse clones that express B-220 surface antigen, contain Ig genes in germ-line configuration, and generate B lymphocytes in vivo. Cell 41:727-734.
69. Peng, C., et al. 2010. PTEN is a tumor suppressor in CML stem cells and BCR-ABL-induced leukemias in mice. Blood 115:626-635.
70. Polevoda, B., and F. Sherman. 2003. N-terminal acetyltransferases and sequence requirements for N-terminal acetylation of eukaryotic proteins. J. Mol. Biol. 325:595-622.
71. Porter, A. C., and R. R. Vaillancourt. 1998. Tyrosine kinase receptor-activated signal transduction pathways which lead to oncogenesis. Oncogene 17:1343-1352.
72. Rodrigues, G. A., and M. Park. 1994. Oncogenic activation of tyrosine kinases. Curr. Opin. Genet. Dev. 4:15-24.
73. Sabe, H., M. Okada, H. Nakagawa, and H. Hanafusa. 1992. Activation of c-Src in cells bearing v-Crk and its suppression by Csk. Mol. Cell. Biol. 12:4706-4713.
74. Savona, M., and M. Talpaz. 2008. Getting to the stem of chronic myeloid leukaemia. Nat. Rev. Cancer 8:341-350.
75. Scheijen, B., and J. D. Griffin. 2002. Tyrosine kinase oncogenes in normal hematopoiesis and hematological disease. Oncogene 21:3314-3333.
76. Schindler, T., et al. 2000. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science 289:1938-1942.
77. Shah, K., and K. M. Shokat. 2002. A chemical genetic screen for direct v-Src substrates reveals ordered assembly of a retrograde signaling pathway. Chem. Biol. 9:35-47.
78. Shinohara, H., T. Yasuda, and Y. Yamanashi. 2004. Dok-1 tyrosine residues at 336 and 340 are essential for the negative regulation of Ras-Erk signalling, but dispensable for rasGAP-binding. Genes Cells 9:601-607.
79. Sirvent, A., C. Benistant, and S. Roche. 2008. Cytoplasmic signalling by the c-Abl tyrosine kinase in normal and cancer cells. Biol. Cell 100:617-631.
80. Songyang, Z., Y. Yamanashi, D. Liu, and D. Baltimore. 2001. Domaindependent function of the rasGAP-binding protein p62Dok in cell signaling. J. Biol. Chem. 276:2459-2465.
81. + signaling in B cells. EMBO J. 26:1140-1149.
82. Suzu, S., et al. 2000. p56(dok-2) as a cytokine-inducible inhibitor of cell proliferation and signal transduction. EMBO J. 19:5114-5122.
83. Tait, S. W., et al. 2007. Apoptosis induction by Bid requires unconventional ubiquitination and degradation of its N-terminal fragment. J. Cell Biol. 179:1453-1466.
84. Titz, B., et al. 2010. The proximal signaling network of the BCR-ABL1 oncogene shows a modular organization. Oncogene 29:5895-5910.
85. Treier, M., L. M. Staszewski, and D. Bohmann. 1994. Ubiquitin-dependent c-Jun degradation in vivo is mediated by the delta domain. Cell 78:787-798.
86. Van Slyke, P., et al. 2005. Dok-R mediates attenuation of epidermal growth factor-dependent mitogen-activated protein kinase and Akt activation through processive recruitment of c-Src and Csk. Mol. Cell. Biol. 25:3831-3841.
87. Wade, M., Y. V. Wang, and G. M. Wahl. 2010. The p53 orchestra: Mdm2 and Mdmx set the tone. Trends Cell Biol. 20:299-309.
88. Wang, X., et al. 2007. Ubiquitination of serine, threonine, or lysine residues on the cytoplasmic tail can induce ERAD of MHC-I by viral E3 ligase mK3. J. Cell Biol. 177:613-624.
89. Wang, X., and X. Jiang. 2008. Post-translational regulation of PTEN. Oncogene 27:5454-5463.
90. Wick, M. J., L. Q. Dong, D. Hu, P. Langlais, and F. Liu. 2001. Insulin receptor-mediated p62dok tyrosine phosphorylation at residues 362 and 398 plays distinct roles for binding GTPase-activating protein and Nck and is essential for inhibiting insulin-stimulated activation of Ras and Akt. J. Biol. Chem. 276:42843-42850.
91. Wisniewski, D., A. Strife, D. Wojciechowicz, C. Lambek, and B. Clarkson. 1994. A 62-kilodalton tyrosine phosphoprotein constitutively present in primary chronic phase chronic myelogenous leukemia enriched lineage negative blast populations. Leukemia 8:688-693.
92. Woodring, P. J., et al. 2004. c-Abl phosphorylates Dok1 to promote filopodia during cell spreading. J. Cell Biol. 165:493-503.
93. Yamanashi, Y., and D. Baltimore. 1997. Identification of the Abl- and ras-GAP-associated 62 kDa protein as a docking protein, Dok. Cell 88:205-211.
94. Yasuda, T., et al. 2007. Dok-1 and Dok-2 are negative regulators of T cell receptor signaling. Int. Immunol. 19:487-495.
95. Yasuda, T., et al. 2004. Role of Dok-1 and Dok-2 in myeloid homeostasis and suppression of leukemia. J. Exp. Med. 200:1681-1687.
96. Yoo, Y., H. J. Ho, C. Wang, and J. L. Guan. 2010. Tyrosine phosphorylation of cofilin at Y68 by v-Src leads to its degradation through ubiquitin-proteasome pathway. Oncogene 29:263-272.
97. Zhang, Y., et al. 2004. Molecular basis of distinct interactions between Dok1 PTB domain and tyrosine-phosphorylated EGF receptor. J. Mol. Biol. 343: 1147-1155.
98. Zhao, M., J. A. Janas, M. Niki, P. P. Pandolfi, and L. Van Aelst. 2006. Dok-1 independently attenuates Ras/mitogen-activated protein kinase and Src/cmyc pathways to inhibit platelet-derived growth factor-induced mitogenesis. Mol. Cell. Biol. 26:2479-2489.
99. Zhao, M., et al. 2001. Phosphoinositide 3-kinase-dependent membrane recruitment of p62(dok) is essential for its negative effect on mitogen-activated protein (MAP) kinase activation. J. Exp. Med. 194:265-274.